Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2490 | NT-I7 Wiki | 1.00 |
| drug1108 | Cross Sectional study using scientifically validated psychometric Scales Wiki | 1.00 |
| drug602 | Blood for research purposes Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Lymphopenia is common in patients with COVID-19 and is associated with worse clinical outcomes. NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T cell counts with a well-tolerated safety profile in humans. In this study, patients who have tested positive for SARS-CoV-2 by PCR testing without severe disease and with ALC <1500 cells/mm3 will be enrolled.
Description: The safe tolerated dose is defined as the dose level immediately below the dose level at which 1 patient of a cohort of 3 patients experiences dose-limiting toxicity within 14 days after administration of NT-I7 Dose limiting toxicities (DLT) are defined as: A serious adverse event that is at least possibly related to NT-I7 A grade 3 or higher adverse event that is at least possibly related to NT-I7 (excluding injection site swelling, irritation or discomfort) A clinically significant lab abnormality that is at least possibly related to NT-I7
Measure: Safe and tolerable dose of NT-I7 (Phase I only) Time: Completion of DLT assessment window of Phase I portion of study (estimated to be 8 months)Description: -Using PCR from nasopharyngeal swab, oropharyngeal swab or saliva
Measure: Change in SARS-CoV-2 viral load Time: From baseline to Day 7Description: -Using PCR from nasopharyngeal swab, oropharyngeal swab or saliva
Measure: Change in SARS-CoV-2 viral load Time: From baseline to Day 14Description: -A treatment emergent adverse event (TEAE) is defined as any event that begins or worsens on or after date of first dose of study treatment.
Measure: Incidence of treatment-emergent adverse events Time: From baseline through Day 21Description: -If quantitative PCR is not available
Measure: Number of participants by PCR result status (positive or negative) Time: -From baseline to Day 7Description: -If quantitative PCR is not available
Measure: Number of participants by PCR result status (positive or negative) Time: From baseline to Day 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports